17.04.2007

The U.S. Food and Drug Administration announced its first approval of a vaccine for human use in the United States against the H5N1 influenza virus.
The vaccine, manufactured by sanofi pasteur was obtained from a human strain and was found to be able to develop adequate immunity against H5N1 in 45 percent of the people receiving two doses of the vaccine.
The H5N1 vaccine will not be sold commercially. For the time being, the manufacturer, sanofi pasteur Inc. makes the vaccine only for the U.S. government for inclusion within the U.S. Strategic National Stockpile for distribution by public health officials if needed.